Today, we will disassemble the vaccine industry chain again. Previously, we have tracked vaccine related industries, such as 13 valent pneumonia, rabies, influenza, covid-19, HPV and animal vaccines. See the industrial chain report library for details.
On this list, 13 price pneumonia ranks first, and there is a huge gap between China’s approved shipment value and global sales. In addition, multi linked and multivalent seedlings are also the development trend in the future.
At present, the participants of 13 valent pneumonia vaccine in China mainly include Shenzhen Kangtai Biological Products Co.Ltd(300601) , Walvax Biotechnology Co.Ltd(300142) . In this tracking, we take Shenzhen Kangtai Biological Products Co.Ltd(300601) as an example to analyze the pipeline under research.
Shenzhen Kangtai Biological Products Co.Ltd(300601) started with hepatitis B vaccine. In 2009, it purchased the “Min Hai bio” product line, and expanded its product line to multiple multi valent vaccines. Since 2017, the rapid and large-scale production of Silian seedlings has driven high performance growth. Heavy varieties have entered the approval stage since 2021, opening a new round of growth.
In this case, from the perspective of recent growth, in the third quarterly report of 2021, its revenue reached 2.377 billion yuan, a year-on-year increase of 67.37%; The net profit attributable to the parent company was 1.036 billion yuan, a year-on-year increase of 139.13%.
In terms of its income composition, it is mainly class II vaccine, accounting for 98.62%. Among the listed products, quadruple vaccine and 23 valent pneumonia vaccine are the main sources of income. In addition, the 13 valent pneumonia vaccine and covid-19 vaccine listed in 2021 have also become new products.
Here are some questions worth thinking about:
1) how to calculate the sales space of the varieties that have been listed at present?
2) what are the potential varieties to be tracked in the current pipeline under research, and what is the future competition pattern?
